Acumen Pharmaceuticals (ABOS) Assets (2020 - 2026)

Acumen Pharmaceuticals has disclosed Assets across 7 years of filings, most recently posting $116.0 million for Q2 2026.

• In Q2 2026, Assets fell 32.51% year-over-year to $116.0 million; the TTM figure through Jun 2026 stood at $116.0 million (down 32.51% YoY), while the FY2025 annual figure was $122.8 million, down 48.6% from the prior year.
• Assets came in at $116.0 million for Q2 2026 at Acumen Pharmaceuticals, down from $133.6 million in the prior quarter.
• In the past five years, Assets ranged from a high of $310.1 million in Q4 2023 to a low of $116.0 million in Q2 2026.
• Average Assets over 5 years is $210.0 million, with a median of $203.9 million recorded in 2022.
• Year-over-year, Assets jumped 190.2% in 2022 and plunged 48.6% in 2025.
• Over 5 years, Assets stood at $196.6 million in 2022, then soared by 57.75% to $310.1 million in 2023, then declined by 22.94% to $239.0 million in 2024, then plunged by 48.6% to $122.8 million in 2025, then dropped by 5.56% to $116.0 million in 2026.
• Per Business Quant data, the three most recent Assets figures were $116.0 million in Q2 2026, $133.6 million in Q1 2026, and $122.8 million in Q4 2025.